The relationship between insulin signaling dysfunction and [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- has emerged as one of the most significant research
frontiers in neurodegeneration. Growing evidence demonstrates that brain insulin resistance — sometimes referred to as "Type 3 Diabetes" —
represents a fundamental pathological mechanism linking metabolic dysfunction to cognitive decline and neuronal death. While not an
officially recognized diagnostic category by the WHO or ADA, the concept captures the convergence of impaired [brain insulin signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling[/entities/[brain-insulin-signaling--TEMP--/entities)--FIX-- with
the hallmark pathologies of AD, including [Amyloid-Beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta--TEMP--/proteins)--FIX-- accumulation, [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- hyperphosphorylation, [neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--, and [synaptic[/entities/[synapse[/entities/[synapse[/entities/[synapse[/entities/[synapse--TEMP--/entities)--FIX--
[2]
Epidemiological studies consistently show that [Type 2 diabetes[/diseases/[type-2-diabetes[/diseases/[type-2-diabetes[/diseases/[type-2-diabetes[/diseases/[type-2-diabetes--TEMP--/diseases)--FIX-- mellitus (T2DM) approximately doubles the risk of developing Alzheimer's
[3]
in the brain contributes to neurodegeneration and have opened new therapeutic avenues including GLP-1 receptor agonists, intranasal insulin,
[4]
¶ Brain Insulin Sources and Receptors
[5]
In the healthy brain, insulin signaling performs several essential functions:
[6]
[7]
[8]
[9]
[10]
The canonical insulin signaling pathway in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- involves:
- Insulin binds to insulin receptor (IR) → receptor autophosphorylation
- Activation of insulin receptor substrate ([IRS-1[/entities/[irs1[/entities/[irs1[/entities/[irs1[/entities/[irs1--TEMP--/entities)--FIX--/IRS-2)
- PI3K activation → PIP2 to PIP3 conversion
- Akt (protein kinase B) phosphorylation and activation
- [GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- inhibition via phosphorylation at Ser9
- Downstream effects on [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- phosphorylation, glycogen synthesis, and cell survival
[11]
Postmortem brain studies from AD patients demonstrate significantly reduced insulin receptor expression and downstream signaling activity in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--. Specifically:
[12]
[13]
[14]
[15]
¶ Amyloid-Beta and Insulin Resistance: A Bidirectional Relationship
[Amyloid-Beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta--TEMP--/proteins)--FIX-- oligomers directly impair insulin signaling by:
[16]
[17]
[18]
Conversely, insulin resistance promotes [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- accumulation through:
[19]
-
**Altered [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--:435-439. DOI)" title="[Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- [Amyloid-Beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta[/proteins/[amyloid-beta--TEMP--/proteins)--FIX-- peptides. Nature. 2003;423(6938):435-439. DOI)">20
-
Reduced [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance: Insulin resistance impairs [microglial[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/[microglia/GSK-3β), a primary kinase for [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- phosphorylation:)
-
Insulin normally suppresses [GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- activity through Akt-mediated phosphorylation
-
In insulin-resistant states, Akt activity declines, removing this inhibition
[22]
[23]
FDG-PET imaging studies consistently demonstrate reduced cerebral glucose metabolism in AD, particularly in temporoparietal regions:
- Glucose hypometabolism precedes clinical symptoms by 10-20 years and is detectable in cognitively normal carriers of the [APOE[/[24[/[24[/[24[/[24[/[24[/[24[/[24[/24)
[25]
[27]
¶ neuroinflammation and Insulin Resistance
[neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX-- and insulin resistance form a vicious cycle:
[29]
[30]
[31]
¶ Type 2 Diabetes and Alzheimer's Disease Risk
Multiple large-scale epidemiological studies establish a strong link:
[32]
[33]
[34]
[36]
[37]
[38]
GLP-1 receptor agonists have emerged as one of the most promising therapeutic strategies for AD-related insulin resistance:
[41]
[25]
[27]
Intranasal insulin delivers insulin directly to the brain via the olfactory and trigeminal nerve pathways, bypassing the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--:
[42]
[43]
- Effects may be modulated by [APOE:897-906. PubMed)">44
[45]
[46]
[47]
[48]
¶ Dietary and Lifestyle Interventions
[49]
[51]
[52]
The concept of AD as "Type 3 Diabetes" was formally proposed by Suzanne de la Monte and Jack Wands in 2005-2008, based on findings that AD brains show:
- Markedly reduced expression of insulin, IGF-1, and their receptors
- Reduced expression of insulin receptor substrate [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins
[53]
While the Type 3 Diabetes label captures the importance of brain insulin resistance in AD, most experts consider it an oversimplification because:
- Not all AD patients have measurable insulin resistance
- The relationship is likely bidirectional and part of a broader metabolic syndrome
- [Amyloid] and [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- pathology] have multiple drivers beyond insulin signaling
[38]
Nevertheless, the hypothesis has been transformative in directing research attention toward metabolic interventions and has led to multiple clinical trials targeting brain insulin signaling.
The study of Insulin Resistance And Metabolic Dysfunction In Alzheimer's Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[2]
beyond macrovascular complications. Importantly, many Alzheimer's patients exhibit evidence of brain insulin resistance even in the absence
of peripheral diabetes, indicating that cerebral insulin signaling dysfunction may be a primary pathological process rather than simply a
[3]
[4]
[5]
[6]
[7]
Postmortem studies of [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- brain tissue reveal significant reductions in Akt phosphorylation and activity. In the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and prefrontal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- of
[8]
neurofibrillary tangle burden, suggesting that Akt dysfunction contributes to disease progression.
The mechanism of Akt impairment involves multiple factors:
[9]
[10]
[11]
¶ GSK-3β Activation and Tau Pathology
[12]
Active [GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- directly phosphorylates [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- protein" title="[Rickle A, Bogdanovic N, Bhatt MP, et al. Akt activity in Alzheimer's Disease and other neurodegenerative disorders. Neuroreport. 2004;15(6):955-959. PubMed)">14.
[15]
[16]
Evidence supporting this mechanism includes:
[17]
[18]
[19]
[20]
Multiple mechanisms contribute to cerebral glucose hypometabolism in Alzheimer's Disease:
[21]
[22]
3. Neuronal loss: Synaptic and neuronal loss directly reduces metabolic demand
[23]
The hypometabolism observed in Alzheimer's Disease is distinct from that seen in other dementias, with relative preservation of the sensorimotor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--—patterns that inform differential diagnosis.
[29]
[30]
[31]
The effects appear to depend on apolipoprotein E genotype, with APOE4 carriers showing altered responsiveness—a finding with important implications for personalized therapy.
Additional brain insulin resistance include:
[32]
[33]
[34]
Brain insulin resistance intersects with multiple other Alzheimer's Disease pathological pathways:
- [Amyloid] pathology: Impaired insulin signaling affects [amyloid precursor protein)" title="Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6:540-548. [DOI))">35
[36]
[37]
The recognition of brain insulin resistance as a core pathological mechanism in Alzheimer's Disease has profound implications for understanding disease pathogenesis and developing new [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments. The Type 3 Diabetes hypothesis has generated substantial research interest and identified promising therapeutic targets, including GLP-1 receptor agonists and intranasal insulin. While further clinical trials are needed, metabolic interventions represent one of the most actively pursued avenues for disease-modifying therapy in Alzheimer's Disease.
The relationship between Alzheimer's Disease and metabolic dysfunction has emerged as one of the most significant frontiers in understanding neurodegenerative disease pathogenesis. The concept of Alzheimer's Disease as "Type 3 Diabetes" reflects growing evidence that brain insulin resistance represents a fundamental pathological mechanism, distinct from peripheral insulin resistance in [Type 2 diabetes[/diseases/[type-2-diabetes[/diseases/[type-2-diabetes[/diseases/[type-2-diabetes[/diseases/[type-2-diabetes--TEMP--/diseases)--FIX-- yet sharing core molecular features. This page examines the evidence linking insulin signaling dysfunction to Alzheimer's Disease pathogenesis, the downstream consequences for [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- pathology and synaptic integrity, and the therapeutic potential of metabolic interventions.
The following resources provide additional data on genes and proteins related to Insulin Resistance and Metabolic Dysfunction in Alzheimer's Disease:
- [de la Monte SM, Wands JR. Alzheimer's Disease is type 3 diabetes — evidence reviewed. J Diabetes Sci Technol. 2008;2(6:1101-1113. DOI
- [Nguyen TT, Ta QTH, Nguyen TKO, et al. Type 3 diabetes and its role implications in Alzheimer's Disease. Int J Mol Sci. 2020;21(9]:3165. . . DOI
- [Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4(6]:640-650. . . DOI
- [Hölscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs. 2020;29(4]:333-348. . . DOI
- [Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature. 1978;272(5656]:827-829. . . DOI
- DOI
- [Pearson-Leary J, McNay EC. Novel roles for the insulin-regulated glucose transporter-4 in hippocampally dependent memory. J Neurosci. 2016;36(47]:11851-11864. . . DOI
- Kitagishi Y, Nakanishi A, Ogura Y, et al. Dietary regulation of PI3K/AKT pathway in Alzheimer's Disease. Alzheimers Res Ther. 2014;6(3]:35.
- PubMed
- [Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and Amyloid-Beta peptide in Alzheimer's Disease. Neurobiol Aging. 2006;27(2]:190-198. . . DOI
- [Jolivalt CG, Lee CA, Beiswenger KK, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice. Neuroscience. 2008;155(3]:567-577. PubMed
- [Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's Disease — is this type 3 diabetes? J Alzheimers Dis. 2005;7(1]:63-80. PubMed
- [Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's Disease patients is associated with IGF-1 resistance, [IRS-1[/entities/[irs1[/entities/[irs1[/entities/[irs1[/entities/[irs1--TEMP--/entities)--FIX-- dysregulation, and cognitive decline. J Clin Invest. 2012;122(4]:1316-1338. . . DOI
- [Rickle A, Bogdanovic N, Bhatt MP, et al. Akt activity in Alzheimer's Disease and other neurodegenerative disorders. Neuroreport. 2004;15(6]:955-959. PubMed
- [Yarchoan M, Toledo JB, Lee EB, et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- pathology in Alzheimer's Disease and [tauopathies[/mechanisms/[tauopathies[/mechanisms/[tauopathies[/mechanisms/[tauopathies[/mechanisms/[tauopathies--TEMP--/mechanisms)--FIX--. Acta Neuropathol. 2014;128(5]:679-689. . . DOI
- DOI
- [Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's Disease-associated Aβ oligomers. J Clin Invest. 2012;122(4]:1339-1353. . . DOI
- [De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci U S A. 2009;106(6]:1971-1976. PubMed
- DOI
- [Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's Disease Amyloid-Beta peptides. Nature. 2003;423(6938]:435-439. . . DOI
- [Mullins RJ, Diehl TC, Chia CW, Kapogiannis D. Insulin resistance as a link between [Amyloid-Beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and [tau[/proteins/[tau[/proteins/[tau[/proteins/[tau[/proteins/[tau--TEMP--/proteins)--FIX-- pathologies in Alzheimer's Disease. Front Aging Neurosci. 2017;9:118. . . DOI
- DOI
- PubMed
- [Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and [oxidative stress in preclinical Alzheimer's Disease. Ann N Y Acad Sci. 2008;1147:180-195. DOI
- [Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's Disease vasculo-neuronal dysfunction. Nature. 2015;521(7551]:174-178. . . DOI
- [Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's Disease. J Alzheimers Dis. 2018;62(3:1403-1416. DOI
- [McEwen BS, Reagan LP. Glucose transporter expression in the brain. Psychopharmacology (Berl. 2004;174(4]:503-513. PubMed)
- Heneka MT, Carson MJ, El Khoury J, et al. neuroinflammation in Alzheimer's Disease. Lancet Neurol. 2015;14(4):388-405.
- [De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and [mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer's Disease. Diabetes. 2014;63(7]:2262-2272. DOI
- Tarantino L, Paolillo M, Formisano L, et al. neuroinflammation and insulin resistance in Alzheimer's Disease. J neuroinflammation. 2020;17:305.
- [Ulland TK, Song WM, Bhatt MP, et al. [TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX-- maintains microglial metabolic fitness in Alzheimer's Disease. Cell. 2017;170(4]:649-663. . . DOI
- [Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999;53(9]:1937-1942. . . DOI
- [Willette AA, Johnson SC, Birdsill AC, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 2015;11(5]:504-510. . . DOI
- [Young SE, Mainous AG 3rd, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care. 2006;29(12]:2688-2693. PubMed
- [Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6:540-548. DOI
- [Whitmer RA, Gustafson DR, Barrett-Connor E, et al. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71(14]:1057-1064. PubMed
- [Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2021;141(6]:773-786. PubMed
- [Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer's Disease. Nat Rev Neurol. 2018;14(3]:168-181. . . DOI
- [Edison P, Femminella GD, Ritchie CW, et al. Liraglutide in mild to moderate Alzheimer's Disease: results of the ELAD phase 2b trial. Nat Med. 2025. . . DOI
- [Cummings J, Bauzon J, Johannsen P, et al. EVOKE and EVOKE+: design of two phase 3 studies evaluating semaglutide in early-stage symptomatic Alzheimer's Disease. Alzheimers Res Ther. 2024;16:282. . . DOI
- [Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's Disease models. Neuropharmacology. 2018;136(Pt B]:251-259. . . DOI
- [Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer's Disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69(1]:29-38. . . DOI
- [Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29(10]:1326-1334. PubMed
- [Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's Disease dementia. J Alzheimers Dis. 2015;44(3]:897-906. PubMed
- [Craft S, Raman R, Chow TW, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer's Disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9]:1099-1109. . . DOI
- [Campbell JM, Stephenson MD, de Courten B, et al. Metformin use associated with reduced risk of dementia in patients with diabetes. J Alzheimers Dis. 2018;65(4]:1225-1236. . . DOI
- [Burns DK, Alexander RC, Welsh-Bohmer KA, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's Disease (TOMORROW]. Lancet Neurol. 2021;20(7]:537-547. PubMed
- [Perna M, Koyani SJ, Ntzouvani A, et al. SGLT2 inhibitors and the brain: a potential therapeutic approach for Alzheimer's Disease. Pharmaceutics. 2021;13(11]:1854. PubMed
- [Croteau E, Cunnane SC, Castellano CA. Ketogenic diet enhances brain metabolism and mitochondrial function. J Alzheimers Dis. 2021;80(s1]:S75-S87. PubMed
- [Scarmeas N, Stern Y, Tang MX, et al. Mediterranean diet and risk for Alzheimer's Disease. Ann Neurol. 2006;59(6:912-921. DOI
- [Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30(9]:464-472. . . DOI
- [Mattson MP, Moehl K, Ghena N, et al. Intermittent metabolic switching, [neuroplasticity and brain health. Nat Rev Neurosci. 2018;19(2]:63-80. DOI
- [de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's Disease. J Alzheimers Dis. 2005;7(1]:45-61. PubMed
- Last updated: 2026-02-27.
- [Metabolic Dysfunction[/mechanisms/[metabolic-dysfunction-pathway[/mechanisms/[metabolic-dysfunction-pathway[/mechanisms/[metabolic-dysfunction-pathway[/mechanisms/[metabolic-dysfunction-pathway--TEMP--/mechanisms)--FIX--
- [Type 3 Diabetes Hypothesis[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [Brain Insulin Resistance[/mechanisms/[insulin-signaling[/mechanisms/[insulin-signaling[/mechanisms/[insulin-signaling[/mechanisms/[insulin-signaling--TEMP--/mechanisms)--FIX--
- [GLP-1 Agonists[/treatments/[glp-1-agonists[/treatments/[glp-1-agonists[/treatments/[glp-1-agonists[/treatments/[glp-1-agonists--TEMP--/treatments)--FIX--
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
54 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 51%